r conversation ask the
following: "Do you know of anyone who might benefit from my services or products?"
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
rget="_new"href="http://EzineArticles.com/?id=39524">Asking is a powerful tactic to increase sales.
Incorporateeasingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
asking for 3 solid referrals within your proposal or statement of work.
Establishing a process for consistency se
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
uring new referrals from satisfied and loyal clients is truly a "no brainer."
Meet with other members of your netwoand physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
king groups or strategic alliances and learn more about them so that you can “pitch” their services or products if and when
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
appropriate.
Referrals are not a one way street. You must also think of others with whom you have established bu
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
siness relationships. Referrals are part of the Law of Attraction and the Law of Abundance.
Always use the referredd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
person’s name (with permission) when contacting a referral.
By using the name of the referral source warms a col
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
call into a warm cold.
Update the referring individual as to the progress of the referral.
By keeping thtions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
referring individual aware of the progress shows that you are a person of high integrity.
Establish a monitoring st?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
stem for all pitches and catches so that you can determine if your catches (closed deals) land in your glove or end up bein
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
a run-a-away (lost deal).
Keeping track of your referrals is necessary so that you not only acknowledge the refe
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ral source, but can determine the source of all new sales. Measuring your activity allows you to work smarter not harder.
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
If you are not actively using referrals as a strategy and a tactic to increase sales to your bottom line, you are potential
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
y missing thousands of dollars in new revenue. And after all, business is all about revenue, no ifs, no buts and no maybes
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products